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The seminal discovery of the common
origin of the Drosophila segment polarity
gene Wingless and the murine pro-
tooncogene Int-1 (Rijsewijk et al., 1987)
heralded the start of a remarkable suc-
cess story of interdisciplinary science.
Drosophila geneticists, immunologists,
frog developmental biologists, cell biolo-
gists, and molecular oncologists all pro-
vided essential components
of a signaling pathway that is
now referred to as the
canonical Wnt cascade. The
term Wnt derives from the
contraction of the gene
names Wingless and Int-1.
Wnt genes, of which the
human genome encodes
almost twenty, are found
throughout the animal king-
dom. Secreted Wnt factors
control virtually every devel-
opmental decision in the life-
time of an animal. The
central player in the cascade
is a cytoplasmic protein
termed β-catenin, whose
stability is regulated by the
APC complex. When Wnt
receptors are not engaged,
kinases in the APC complex
phosphorylate β-catenin,
thus targeting the latter pro-
tein for rapid destruction.
When the receptors are acti-
vated by their Wnt ligands,
the intrinsic kinase activity
of the APC complex is inhib-
ited. As a consequence, stable nonphos-
phorylated β-catenin accumulates and
makes its way into the nucleus, where it
engages the N terminus of DNA binding
proteins of the Tcf/Lef family. The human
genome encodes four Tcf/Lef proteins. In
the absence of a Wnt signal, these DNA
binding proteins occupy target genes to
repress their transcription. The interac-
tion with β-catenin transiently converts
Tcf factors from repressors into tran-
scriptional activators. A Wnt signal is
thus translated into the transient tran-
scription of a Tcf target gene program
(Huelsken and Birchmeier, 2001).
The APC gene was originally discov-
ered as the culprit in a hereditary cancer
syndrome termed familiar adenomatous
polyposis (FAP). FAP patients develop
large numbers of colon polyps in early
adulthood. The patients inherit one
defective APC allele. Individual polyps
are clonal outgrowths of epithelial cells in
which the second APC allele is inactivat-
ed. Soon after the discovery of APC in
FAP families, it was realized that both
APC alleles were also inactivated in up
to 80% of sporadic colorectal cancers
(Kinzler and Vogelstein, 1996). The loss
of APC was subsequently found to
induce the inappropriate stabilization
and accumulation of β-catenin
(Rubinfeld et al., 1996). This observation
had two important implications. It
assigned to APC a crucial negative regu-
latory function in the Wnt cascade, and 
it suggested that the inappropriate 
activation of the Wnt cascade in the
absence of APC somehow transformed
epithelial cells. It was subsequently
found that Tcf reporter constructs such
as pTOPFLASH, normally activated only
upon Wnt signaling, were inappropriately
active in APC mutant cancer cells
(Korinek et al., 1997). Tcf4
was the pertinent Tcf factor in
the intestine. In the relatively
rare cases of colorectal can-
cers with wt APC, activating
point mutations were found in
β-catenin, again leading to the
inappropriate formation of
active β-catenin/Tcf4 com-
plexes (Morin et al., 1997).
Why would the constitu-
tive activity of a transcription
factor immortalize intestinal
epithelial cells? Tcf4 proved to
be of profound physiological
importance for the homeosta-
sis of the intestinal epithelium.
Proliferative epithelial progen-
itors occupy the crypts in the
wall of the intestine. Cells flow
from these crypts onto finger-
like epithelial protrusions
termed villi. Upon exit from the
crypts, proliferation subsides
and the cells rapidly differenti-
ate to live for another 3–5
days. Cellular death ensues
when the top of the villus is
reached. In Tcf4−/− mice, the
villus epithelium is intact, but the crypt
progenitor compartment is entirely
absent at birth. This implies that physio-
logical Wnt signaling is required for
maintenance of the crypt progenitor phe-
notype (Korinek et al., 1998). Indeed,
nuclear β-catenin, the hallmark of active
Wnt signaling, occurs throughout the
crypts of adult intestine (Figure 1).
Multiple studies have addressed the
nature of the Tcf4 target gene program in
colorectal cancer. Among others, c-Myc
(He et al., 1998) and CyclinD1 (Tetsu
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β-catenin and Tcf4 are the downstream effectors of the Wnt signaling cascade. In colorectal cancer, mutations in Wnt cas-
cade genes such as APC lead to the inappropriate formation of β-catenin/Tcf4 complexes. Earlier work has predicted that
disruption of the β-catenin/Tcf4 protein-protein interaction could revert the proliferative phenotype of colorectal cancer
cells. In this issue of Cancer Cell, Shivdasani and colleagues (Lepourcelet et al., 2004) have explored high-throughput
screening of compound libraries in a search for small molecule inhibitors of the Wnt cascade. Ultimately, such inhibitors
could become a novel class of smart anticancer drugs.
Figure 1. A small adenoma in the intestine of APC+/− mice
A, adenoma; V, villus; C, crypt; M, muscle wall of the small intestine.
The section is stained for the presence of β-catenin. Note the accu-
mulation of β-catenin in the adenoma, but also in the crypts. Courtesy
of H. Begthel.
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and McCormick, 1999) appear to be
essential components of this program in
transformed intestinal epithelial cells.
Recently, a global assessment of the
Tcf4 target gene program in colorectal
cancer cells was made by DNA arraying
(van de Wetering et al., 2002).This study
revealed that Tcf4 drives a program in
colorectal cancer cells that is shared with
that of crypt cells. APC−/− adenoma cells
thus represent the transformed counter-
parts of crypt progenitor cells. Once the
Wnt cascade is mutationally activated,
the adenoma cells maintain their progen-
itor outfit indefinitely.This allows the ade-
nomas to persist for many years in the
human intestine, providing ample oppor-
tunity for the acquisition of further muta-
tions to ultimately become a highly
malignant, invasive, and metastasizing
carcinoma.
Several studies have found that inhi-
bition of the initiating transforming event
in colorectal cancer cell lines, i.e., 
the inappropriate formation of a 
β-catenin/Tcf4 complex, drives these
cells out of cycle in the face of multiple
other acquired mutations in their genome
(e.g., Tetsu and McCormick, 1999). Tcf4
inhibition actually induces colorectal can-
cer cells to differentiate into a villus
epithelial phenotype, essentially complet-
ing their life cycle after many years’ delay
(van de Wetering et al., 2002). The accu-
mulated data make a strong argument to
consider the β-catenin/Tcf4 complex as a
target for the development of small mole-
cule inhibitors. Unfortunately, there is
general consensus among drug develop-
ers that protein-protein interactions pro-
vide a blind alley for small molecule
programs. Yet, this is exactly what
Shivdasani and colleagues have pursued
(Lepourcelet et al., 2004).
The authors set out to perform a
high-throughput screen in an enzyme-
based protein binding assay, using 
plate-bound β-catenin and a soluble N-
terminal fragment of Tcf4 fused to GST.
Of approximately 7,000 natural com-
pounds, eight displayed reproducible
and dose-dependent inhibition of the
interaction with an IC50 <10 µM. A much
larger screen of 45,000 additional com-
pounds did not yield additional com-
pounds. Six compounds were evaluated
in a range of secondary assays. One
assay explored the inhibition of β-
catenin/Tcf4 binding in colorectal cancer
cell lysates, measured by pulldown of β-
catenin by Tcf4-GST. Inhibition of com-
plex formation in cell lysates was also
measured in a gel retardation assay with
Tcf binding probes. The compounds
were then subjected to a cell-based Tcf
reporter gene assay in a colorectal can-
cer cell line. Most compounds were
found to specifically inhibit the reporter
assay at high nM concentrations. The
colorectal cancer cell line-based studies
were extended by expression analysis of
two Tcf4 targets, c-myc (He et al., 1998)
and Cyclin D1 (Tetsu and McCormick,
1999), which were indeed inhibited
specifically by some of the compounds.
The compounds were then tested in
the classical Xenopus assay for Wnt sig-
naling, which exploits the induction of
embryonic axis duplication upon β-
catenin injection. Three of the com-
pounds inhibited axis duplication
induced by β-catenin, but not by the con-
trol downstream effector Siamois. Lastly,
the compounds were analyzed for their
antiproliferative effects. Three com-
pounds were found to specifically inhibit
proliferation of colorectal cancer cells. In
all, three of the compounds, PKF115-
584, PKF222-815, and CGP049090,
scored consistently in all assays.
Significantly, these compounds share a
core chemical structure.
The study is very good news for any-
one looking at protein-protein interaction
targets for drug development. The classi-
cal approach of high-throughput screen-
ing in a cell-free assay can apparently
yield protein interaction inhibitors that
retain their effects when tested in vivo.
The obvious next step will be the deter-
mination of the structural mechanism by
which these compounds inhibit the β-
catenin/Tcf4 interaction. X-ray structures
exist for the β-catenin/Tcf complex. We
do not know yet to which of the two pro-
teins the compounds bind. Lepourcelet
et al. (2004) note that their best com-
pounds also interfere with the binding of
another partner of β-catenin, namely
APC. While this may complicate the
interpretation of the biological phenome-
na, the observation implies β-catenin as
the direct target of the small molecules.
It will be exciting to see these com-
pounds, or others derived from similar
approaches, move into preclinical stud-
ies. The efforts of many scientists will
guarantee that the success of such stud-
ies will not be hindered by a lack of
insight into the role of the Wnt signaling
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